SB012 / Sterna Biologicals - LARVOL DELTA

Accelerated CDOCKER with GPUs, parallel simulated annealing and fast Fourier transforms. (PubMed, J Chem Theory Comput) - "With this acceleration, we demonstrate that the performance of CDOCKER for re-docking is significantly improved compared with three other popular protein-ligand docking pro- grams on two widely used protein ligand complex datasets - the Astex diverse set and the SB2012 test set. Based on the results presented here, we suggest that the accelerated CDOCKER platform provides a highly competitive docking engine for both rigid-receptor and flexible-receptor docking studies, and will further facilitate continued improvement in the physics-based scoring function employed in CDOCKER docking studies."

Journal

Oligonucleotides-A Novel Promising Therapeutic Option for IBD. (PubMed, Front Pharmacol) - "...Alicaforsen, selectively targets ICAM-1 mRNA...An antisense oligonucleotide against SMAD7 mRNA (mongersen) demonstrated pre-clinical and phase II efficacy in CD, but a phase III clinical trial was stopped due to lack of efficacy...Topical application of cobitolimod was studied in UC patients. We will also discuss two other novel oligonucleotides which act on the GATA3 transcription factor (SB012) and on carbohydrate sulfotransferase 15 (STNM01), which could both represent novel promising therapeutic options for the treatment of UC."

Journal • Review

Sterna Biologicals prepares for phase IIb clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis (Digital Journal) - "Sterna successfully completed Phase IIa trials with SB010 in asthma, as well as eCOPD, and with SB012 in UC and is now preparing for the initiation of Phase IIb trials with SB010 in asthma and SB012 in UC....Sterna is planning to meet with the US Food and Drug Administration (FDA) as well as with the European Medicines Agency (EMA) in H1 2019 to gain their input and advice on the design of the Phase IIb programs for SB010 in asthma and SB012 in UC....Oral formulation prototype for SB012 started, final formulation for Phase II expected in H2 2019."

Regulatory • Trial status